Table 1 Literature review of repeat renal biopsy for AL amyloidosis and comparison with the present case
Author | Year | No | Treatment | From onset of symptoms to start of chemotherapy | Urinary Protein(g/d)/sCr(mg/dl) at 1st Biopsy | At 2nd Biopsy | From 1st to 2nd Biopsy (year) | Reason for 2nd Biopsy | Changes on Renal Pathology * | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hematologic response# | Urinary Protein(g/d)/sCr(mg/dl) | Amyloid deposit | Glomerulosclerosis | Arteriolosclerosis | IFTA | ||||||||
Kyle et al. [9] | 1982 | 1 | MP | 2 y 4 m | 3.9/1.98 | + | 5.1/1.0 | 6* | NR | ↑ | NR | NR | NR |
2 | MP | 8 m | 5.0/3.2 | + | 6.0/1.0 | 4 | NR | ↑ | NR | NR | NR | ||
Yamazaki et al.[7] | 2009 | 1 | VAD + HM/AHSCT | NR | 8.0/1.0 | + | 0.55/1.0 | 1.3 | ↓proteinuria | → | NR | NR | NR |
Okuyama et al.[6] | 2013 | 1 | VRD + HM/AHSCT | NR | 3.4/0.6 | CR | 3.4/0.6 | 1.4* | NR | → | NR | NR | NR |
Nakayama et al.[8] | 2005 | 1 | MP | 3 m | 10/1.3 | + | 0.7/1.7 | 3.2 | AKI with hemodialysis | ↓↓ | ↑ | NR | NR |
Roth et al.[17] | 2013 | 1 | AHSCT | NR | 12.6/1.4 | CR | 3.0/3.5 | 9 | ↑proteinuria, ↑serum Cr | ↑↑ | ↑↑ | ↑ | ↑↑ |
2 | AHSCT | 2 m | 0.6/2.8 | CR | NR/4.7 | 2 | ↑serum Cr | ↑ | ↑ | ↑ | ↑↑ | ||
Zeier et al.[18] | 2003 | 1 | Ifosfamide, HM/AHSCT | 2 m | 7/NR | NR | 1.6/NR | 3.3 | Persistent proteinuria | → | NR | NR | NR |
2 | Ifosfamide, HM/AHSCT | 1 m | 8/2.0 | NR | 0.6/NR | 3.3 | Persistent proteinuria | → | NR | NR | NR | ||
Safadi et al. [10] | 2015 | 1 | HM/AHSCT | 2 m | 10/1.8 | CR | 4/2.1 | 4 | ↑serum Cr | → | → | ↑** | ↓ |
2 | HM/AHSCT, bortezomib and steroids | 1 m | 2.5/1.9 | CR | 3.8/6 | 1.4 | ↑serum Cr | → | → | → | ↑ | ||
Angel-Korman et al. [5] | 2020 | 1 | HM/AHSCT | 0 y | 7.8/1 | CR | 1.3/3.1 | 3.0 | AKI | ↑ | → | ↑ | ↑ |
2 | HM/AHSCT | 0 y | 15.5/1 | CR | 4.7/2.4 | 9.3 | ↑proteinuria and serum Cr | ↑ | ↑ | → | ↑ | ||
3 | HM/AHSCT | 0 y | 5.3/0.7 | CR | 13/0.9 | 7.7 | ↑proteinuria | ↑ | ↑ | ↑ | ↑ | ||
4 | HM/AHSCT | 0 y | 5.9/1.7 | VGPR | 7/2.7 | 3.1 | ↑serum Cr | ↑ | ↑ | ↑ | ↑ | ||
5 | HM/AHSCT | 0 y | 3.3/0.8 | VGPR | 2/2.5 | 11.3 | ↑proteinuria and serum Cr | ↑↑ | → | → | ↑↑ | ||
6 | Rituximab, orpozomib, bendamusitine | 2.0 y | 20/2.9 | VGPR | 11/4.1 | 3.5 | ↑proteinuria and serum Cr | ↑ | ↑ | → | → /↑ | ||
7 | Bor-Dex | 0 y | 13/1.7 | CR | 1.5/2.5 | 2.4 | ↑serum Cr | → | → | → | ↑ | ||
8 | Len-Dex, HM/AHSCT, Len-Dex, Bor-Dex | 0 y | 9.7/1.3 | VGPR | 18/1.2 | 5.2 | ↑proteinuria | → | → | → | → | ||
Torui et al.[19] | 2020 | 1 | VAD + HM + AHSCT | 4 y | 4.89/0.9 | CR | 0.03/0.9 | 3 | To determine the need of further therapy | ↓ | ↑ | NR | NR |
Present case | 2021 | 1 | CyBorD | 1 m | 11.24/0.89 | CR | 9.5/1.0 | 0.75 | Persistent high proteinuria | → /↑ | ↑↑ | ↑ | ↑ |